Now Available: Market Access Impact: HIV (EU5)

Can prescription barriers help the 2nd and 3rd place HIV brands catch up to the runaway market leader?

In the European HIV treatment market, the leading brand is comfortably ahead-but can market barriers help either of the 3rd-place contenders move up to the #2 spot.

Market Access Impact: HIV shows you which brands you're losing share to, which brands you're taking it from, and why.

Market Access Impact: HIV explores how cost concerns and other barriers affect market share for 8 major HIV treatments: Celsentri, Evotaz, Intelence, Isentress, Stribild, Triumeq, Truvada, and Viread.

You'll find out which brands your brand is losing share to, which ones you're taking it from, and why-information you can use to compete more effectively.

Not your market? Click here to see the US report

Reasons to Get this Report

Get Answers to Key Questions about HIV Drug Brands

* Celsentri (maraviroc; ViiV Healthcare): Which two leading FDCs does Celsentri take the most share from?
* Evotaz (atazanavir/cobicistat; BMS): Which barrier do more than twice as many doctors experience with Evotaz than any other brand?
* Intelence (etravirine; Janssen Therapeutics): Is limited availability or patient preference a bigger issue for doctors prescribing Intelence?
* Isentress (raltegravir; Merck & Co.): Isentress and Stribild are prescribed equally. Which brand has better awareness among doctors?
* Stribild (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Gilead): Which market barrier costs Stribild more than twice as much share as any other?
* Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare): Nearly half of Triumeq's share loss is to one other brand. Which one?
* Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead): Which barrier is responsible for over a third of Truvada's net share gain?
* Viread (tenofovir disoproxil fumarate; Gilead): Viread sees a net share gain from all but two surveyed brands. Which two?

Full Report Details at
- http://www.fastmr.com/prod/1180401_market_access_impact_hiv_eu5.aspx?afid=301

Top Takeaways

* Clear winners and losers: The two most prescribed brands have the biggest market share and barrier-related gains, while the two least prescribed brands have the smallest share and the greatest losses.
* Half of brands benefit from barriers: But the two biggest winners see significantly bigger gains than the other two brands.
* Brand awareness is high: With one exception, at least 97% of doctors surveyed are aware of any given brand.
* Barrier effect is uneven: The number of doctors who experience the top 2 market barriers varies greatly from brand to brand.
* No clear advantage for FDCs vs. monotherapies: Of the four most prescribed brands, two are fixed-dose products while the other two are monotherapies.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Market Access Impact: HIV (US)
- Market Access Impact: Psoriasis (EU5)
- Market Access Impact: Renal Cell Carcinoma (EU5)
- NPS+ HIV (EU5)
- Market Access Impact: Psoriasis (US)